Venner, Christopher P
$147,354.00
Canadian Institutes of Health Research | Instituts de recherche en santé du Canada
EF 2016-2017
Canada
A randomized phase II trial of bortezomib-based therapy plus doxycycline vs. bortezomib-based chemotherapy plus standard supportive therapy in cardiac AL amyloidosis